TYK Medicines CEO Boosts Shareholding; Shares Jump 7%

MT Newswires Live

Sep 11

TYK Medicines (HKG:2410) Chief Executive Officer Wu Yusheng has bought HK$2.1 million worth of H shares of the company in a recent open market transaction, according to a Thursday Hong Kong bourse filing.

Shares rose nearly 7% in late-morning trade Friday.

The company said Wu bought 635,000 H shares with his personal funds and indicated he would further increase his shareholding if market conditions are favorable.

Wu's additional purchases of the company's shares will be limited to HK$3 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/news/2666654840"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2666654840\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2666654840?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-11 11:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2666654840","market":"nz","top_or_hot":-1,"title":"TYK Medicines CEO Boosts Shareholding; Shares Jump 7%","media":"MT Newswires Live","content":"<html><body><p> TYK Medicines (HKG:2410) Chief Executive Officer Wu Yusheng has bought HK$2.1 million worth of H shares of the company in a recent open market transaction, according to a Thursday Hong Kong bourse filing.</p><p>Shares rose nearly 7% in late-morning trade Friday.</p><p>The company said Wu bought 635,000 H shares with his personal funds and indicated he would further increase his shareholding if market conditions are favorable.</p><p>Wu's additional purchases of the company's shares will be limited to HK$3 million.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TYK Medicines CEO Boosts Shareholding; Shares Jump 7%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTYK Medicines CEO Boosts Shareholding; Shares Jump 7%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-11 11:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> TYK Medicines (HKG:2410) Chief Executive Officer Wu Yusheng has bought HK$2.1 million worth of H shares of the company in a recent open market transaction, according to a Thursday Hong Kong bourse filing.</p><p>Shares rose nearly 7% in late-morning trade Friday.</p><p>The company said Wu bought 635,000 H shares with his personal funds and indicated he would further increase his shareholding if market conditions are favorable.</p><p>Wu's additional purchases of the company's shares will be limited to HK$3 million.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDCO","symbol_name":"麦迪逊医药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2666654840","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2666654840","pubTimestamp":1789099024,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"TYK Medicines  Chief Executive Officer Wu Yusheng has bought HK$2.1 million worth of H shares of the company in a recent open market transaction, according to a Thursday Hong Kong bourse filing.Shares rose nearly 7% in late-morning trade Friday.The company said Wu bought 635,000 H shares with his personal funds and indicated he would further increase his shareholding if market conditions are favorable.Wu's additional purchases of the company's shares will be limited to HK$3 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDCO":"麦迪逊医药","BK1161":"生物科技","02410":"同源康医药-B"},"translate_title":"TYK Medicines 首席执行官增持股份；股价上涨 7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02410":1,"MDCO":1.5},"content_text":"TYK Medicines (HKG:2410) Chief Executive Officer Wu Yusheng has bought HK$2.1 million worth of H shares of the company in a recent open market transaction, according to a Thursday Hong Kong bourse filing.Shares rose nearly 7% in late-morning trade Friday.The company said Wu bought 635,000 H shares with his personal funds and indicated he would further increase his shareholding if market conditions are favorable.Wu's additional purchases of the company's shares will be limited to HK$3 million.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}